Form 4: ADC Therapeutics Director Timothy Coughlin Receives Significant Equity Grants

ADC Therapeutics SA Director Timothy Coughlin was granted 40,000 restricted stock units and 80,000 stock options as part of his compensation, aligning his interests with shareholder value.

Summary

• Timothy Coughlin, a Director of ADC Therapeutics SA (ADCT), received an annual grant of 40,000 Restricted Stock Units (RSUs) on June 3, 2025.
• These RSUs were granted under the Issuer's 2019 Equity Incentive Plan for his service as a Director and are set to vest one year from the grant date, contingent on his continued service.
• Additionally, Mr. Coughlin received a one-time initial award of 80,000 stock options on June 3, 2025, with an exercise price of $3.59 per share.
• These stock options, also granted under the 2019 Equity Incentive Plan, will vest over four years from the grant date: 1/4 on the first anniversary (June 3, 2026), and the remaining portion vesting monthly in 36 equal installments, subject to continued service.
• Following these transactions, Mr. Coughlin beneficially owns 40,000 common shares (from RSUs) and 80,000 stock options.

Sentiment

Score: 7

Explanation: The document reports a routine equity compensation grant to a director, which is generally a positive sign of alignment between management/board and shareholders. It does not contain any negative news or significant operational updates, but also no overwhelmingly positive news beyond standard compensation.

Positives

• The grant of RSUs and stock options to Director Timothy Coughlin aligns his interests with the long-term performance of ADC Therapeutics SA, incentivizing him to enhance shareholder value.
• The equity grants are part of the company's 2019 Equity Incentive Plan, indicating a structured and approved approach to executive and director compensation.
• The vesting schedules for both RSUs (one year) and stock options (four years) encourage sustained commitment and service from the director.

Negatives

• No specific negative information is contained within this Form 4 filing, as it primarily reports a compensation grant.

Risks

• The value of the granted RSUs and stock options is subject to the future performance of ADC Therapeutics SA's stock price, meaning the actual realized value could be lower than implied at the grant date if the stock price declines.
• The vesting of these equity awards is contingent on Timothy Coughlin's continued service to the Issuer, posing a risk of forfeiture if his service terminates before vesting is complete.

Future Outlook

The document indicates future vesting events for the granted equity awards. The 40,000 RSUs are set to vest one year from the grant date (June 3, 2026), and the 80,000 stock options will vest over four years from June 3, 2025, with 1/4 vesting on the first anniversary and the remainder monthly over 36 installments. These vesting schedules are contingent on the director's continued service.

Industry Context

This Form 4 filing details a standard equity compensation grant to a director, which is a common practice across industries, particularly in the biotechnology and pharmaceutical sectors where long-term incentives are used to retain key talent and align their interests with company growth and shareholder returns. Such grants are typical for publicly traded companies to incentivize leadership.

Comparison to Industry Standards

• The grant of equity awards (RSUs and stock options) to directors is a standard compensation practice in the biotechnology and pharmaceutical industries, similar to companies like Biogen Inc. or Gilead Sciences, Inc., which frequently use such mechanisms to align director interests with long-term shareholder value.
• The vesting schedule for RSUs (one year) and stock options (four years with a cliff and monthly vesting) is within typical industry norms for director compensation, designed to encourage sustained commitment.
• The exercise price of $3.59 for the stock options would be compared to the market price of ADCT shares on the grant date to assess if they were granted at-the-money, in-the-money, or out-of-the-money, which is a common practice for option grants.

Corporate Governance

Related Party Transactions

• The transaction involves a director receiving compensation, which is a related party transaction, but it is a standard, disclosed compensation event under an existing equity plan.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially leading to better long-term performance. Minor potential for dilution from the issuance of shares upon RSU vesting and option exercise.
• Employees: No direct impact on general employees is mentioned.
• Customers: No direct impact on customers is mentioned.
• Suppliers: No direct impact on suppliers is mentioned.
• Creditors: No direct impact on creditors is mentioned.

Next Steps

• The 40,000 Restricted Stock Units are expected to vest on June 3, 2026, subject to continued service.
• The 80,000 Stock Options will begin vesting on June 3, 2026 (1/4 portion), with the remainder vesting monthly over the subsequent 36 months, subject to continued service.

Key Dates

Recommendation

Keywords

ADC Therapeutics SA, ADCT, Form 4, SEC filing, Timothy Coughlin, Director compensation, Restricted Stock Units, RSUs, Stock Options, Equity Incentive Plan, Beneficial Ownership, Executive compensation, Corporate governance